This action reflects our responsibility to protect patients and preserve the integrity of the drug approval process while continuing to provide a transparent, science-based pathway for public input. Regulators are accepting public comments through June 29 to exclude semaglutide, tirzepatide and liraglutide, before any final change to the list of whats approved under 503B is made
It appears to be a news article or policy commentary piece about Medicare coverage decisions regarding GLP-1 medications rather than a peer-reviewed clinical study
Im throwing around some ideas here: Abbvie: Skyrizi + GLP-1 combo for dermatology
Picking a semaglutide supplier isn't a transaction, it's a strategic decision
An attractive candidate for such an activity is, for example, the modulation of the redox state of key proteins involved in DNA repair such as p53 [see 46]." [9] The ability to repair DNA damage that's already been done, rather than only prevent that damage from occurring, is rare